Inimmune Corporation Advances Phase 2 Trial for INI-2004 in Allergic Rhinitis

New treatment strategies for allergic diseases are increasingly focusing on modifying the immune system rather than simply controlling symptoms.

Clinical-stage biotech company Inimmune Corporation has announced the completion of enrollment and dosing of the first patient in its Phase 2 allergen challenge chamber trial evaluating the investigational therapy INI-2004 for Allergic Rhinitis.

Topline results from the study are expected in June 2026.

Why Allergic Rhinitis Needs Better Treatments

Allergic Rhinitis affects hundreds of millions of people worldwide and is one of the most common allergic conditions.

Current treatments usually focus on:

• Symptom control using antihistamines or corticosteroids
• Long-term allergen-specific immunotherapy programs

While these approaches can provide relief, they often require continuous treatment or long therapy timelines.

According to David Burkhart, CEO of Inimmune Corporation, the company aims to develop a therapy that rapidly and durably modifies the immune response driving allergic disease.

Phase 2 Trial Design

The ongoing randomized, placebo-controlled Phase 2 study is designed to evaluate several key outcomes.

Researchers will assess:

• Safety and tolerability
• Clinical efficacy
• Immune biomarker responses

The trial uses a validated allergen exposure chamber model, allowing researchers to precisely measure how patients respond to controlled allergen exposure.

This model is commonly used in allergy research because it provides consistent and measurable clinical conditions.

A “Pipeline in a Product” Approach

INI-2004 is being developed as an allergen-agnostic immunotherapy, meaning it is designed to work regardless of the specific allergen causing the reaction.

The therapy works by activating Toll‑like receptor 4 (TLR4), a key pathway in the body’s innate immune signaling system.

By targeting core immune mechanisms involved in allergic inflammation, the therapy may reprogram immune responses to allergens.

According to Ferdinand Massari, Chief Medical Officer at Inimmune Corporation, this approach gives the therapy broad potential across multiple conditions.

Possible future indications could include:

• Food Allergy
• Allergic Asthma
• Other atopic disorders

This broad potential is why the company describes INI-2004 as a “pipeline in a product.”

What Happens Next?

Once the Phase 2 allergen chamber study is completed, Inimmune Corporation plans to engage with regulatory authorities to determine the next steps for clinical development.

This could include:

• Designing late-stage clinical trials
• Expanding the therapy into additional allergic and asthma-related indications

If the upcoming results are positive, the program could move closer to advanced clinical development and regulatory review.

The Bigger Picture

Allergic diseases are increasing globally, creating demand for treatments that go beyond symptom management.

By targeting innate immune pathways, therapies like INI-2004 aim to change the underlying immune response responsible for allergic reactions.

If successful in later trials, this approach could help simplify treatment and potentially transform how conditions like Allergic Rhinitis and Allergic Asthma are managed in the future.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!